Lipitor (atorvastatin), manufactured by Pfizer, was first approved by the FDA in December 1996. Lipitor is part of the family of drugs known as “statins,” which were well-accepted for secondary prevention (meaning after an initial event) of coronary artery disease (CAD). Ultimately, Lipitor became the most-prescribed statin and ultimately the most prescribed drug in America.
tients with elevateOver the decade following its approval, Lipitor was indicated for use in pad triglycerides, for increasing HDL, for lowering LDL, and in July 2004, Lipitor received an indication for primary prevention even in patients without clinically evidence CAD, just risk factors, in order to reduce the risk of heart attack.
After 2004, a growing body of scientific studies began to demonstrate the risk of type-II diabetes in women ingesting statins such as Lipitor. Pfizer continues to downplay this serious risk by pooling both male and females into the risk-assessment pool, concealing the degree of risks for female patients.
Particularly of note, there remains no clear evidence that Lipitor benefits women who are taking Lipitor for primary prevention of coronary heart disease.